Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Joseph Patti · AGILVAX, INC. · 2020 · $1,152,921 — Agilvax’s AX09 is an Immunotherapy for Triple-Negative Breast Cancer: Agilvax is developing cancer immunotherapies and vaccines with its proprietary virus-like-particle (VLP) platform technology. Agilvax’s lead product, AX09, is an immunotherapy for triple-negative breast cancer (TNBC) targeting can…
Beatrice H Hahn · UNIVERSITY OF PENNSYLVANIA · 2020 · $800,558 — PROJECT SUMMARY Studying Natural SIV Reservoirs and Human Zoonotic Risk, we discovered in the last funding period that certain strains of SIV infecting Old World monkeys and African apes share unexpected antigenic cross- reactivity with HIV-1 in the functionally important V1V2 region of the envelope…
SIMON R BEST · JOHNS HOPKINS UNIVERSITY · 2020 · $195,893 — Dr. Simon Best is a junior faculty member in the Department of Otolaryngology – Head and Neck Surgery at the Johns Hopkins School of Medicine where his clinical practice is dedicated to voice and airway disorders. With the support of this Mentored Career Development Award, Dr. Best seeks to better u…
Clayton C Caswell · VIRGINIA POLYTECHNIC INST AND ST UNIV · 2020 · $77,904 — Project Summary Brucella spp. are bacteria that naturally infect a variety of domesticated and wild animals leading to abortions and sterility, and these bacteria are also capable of causing debilitating human infections, which often result from human exposure to infected animals and animal product…
Christopher Parks · INTERNATIONAL AIDS VACCINE INITIATIVE · 2020 · $2,249,057 — DESCRIPTION (provided by applicant): The overall goal of this HIVRAD consortium is to develop and compare four novel vaccine candidates designed to deliver HIV envelope (Env) trimers mimicking the presentation of Env by HIV infection and ultimately generating broadly neutralizing antibodies (b…
Rebecca Dutch · BOSTON UNIVERSITY MEDICAL CAMPUS · 2020 · $255,651 — SUMMARY Respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) are major causes of respiratory disease and hospitalization in infants. They are also a significant health concern for the elderly, the immunocompromised and individuals who have underlying lung disorders. RSV and HMPV are bo…
Paul A. Goepfert · UNIVERSITY OF ALABAMA AT BIRMINGHAM · 2020 · $662,144 — PROJECT SUMMARY HIV-1 sequence diversity presents a formidable obstacle in the development of an efficacious preventative or therapeutic HIV-1 vaccine. Escape or adaptation from CD8 T cell mediated immune pressure is a major contributor to viral diversity. An adapted epitope (AE) encodes an HLA clas…
Ralph S Baric · UNIV OF NORTH CAROLINA CHAPEL HILL · 2020 · $1,088,512 — ABSTRACT Vaccination represents one of the most effective public health measures for protecting at risk populations from emerging pathogens. However, FDA approved vaccines are lacking for the vast majority of emerging pathogens, and therefore new vaccines and vaccination strategies are needed to pro…
FRANCIS ALI-OSMAN · DUKE UNIVERSITY · 2020 · $160,934 — Historically, stimulation of humoral immunity in the form of antibodies has been the most effective means to provide protection against most viral infections. For this reason, almost all SARS-CoV-2 vaccine efforts are focused on stimulating humoral immunity. At the same time, there is evidence to su…
Milka Koupenova · UNIV OF MASSACHUSETTS MED SCH WORCESTER · 2020 · $418,750 — PROJECT SUMMARY Influenza infection increases the incidence of acute MI (AMI) within the first 7 days after detection and the therapeutic benefit of vaccination is comparable to current therapies for secondary prevention of AMI. Platelets are the blood component central to thrombosis and uncontroll…
GEORGE M SHAW · UNIVERSITY OF PENNSYLVANIA · 2020 · $703,267 — DESCRIPTION (provided by applicant): Recent vaccine studies in nonhuman primates have demonstrated the potential for virus-specific CD8 T cell responses to constrain or eradicate SIV infection. Rhesus CMV (RhCMV) and other persistently and non- persistently replicating vectors have contributed …
Laura Lynn Newcomb · CALIFORNIA STATE UNIV SAN BERNARDINO · 2020 · $110,250 — Influenza virus remains an unmet health issue. Although the virus is controlled with annual vaccines, these exhibit variable efficacy, and slow vaccine production means vaccines are not available during an emerging pandemic. Antivirals can stunt an influenza pandemic, but antivirals become ineffecti…
Ronald G Collman · UNIVERSITY OF PENNSYLVANIA · 2020 · $4,100,153 — CFAR Overview ABSTRACT This competing renewal application for the Penn Center for AIDS Research (CFAR) builds on an outstanding record of dynamic scientific leadership, organizational structure, resources and infrastructure that advance HIV/AIDS research across the integrated campus of the Universit…
Daniel F. Hoft · SAINT LOUIS UNIVERSITY · 2020 · $796,383 — Abstract Influenza is responsible for significant morbidity and mortality worldwide every year and causes severe pandemics when new strains evolve that have not previously circulated in humans. The high viral mutation rate necessitates that new vaccines be generated based on the prevalence of circul…
Darrell J Irvine · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · 2020 · $511,695 — PI: Irvine, Darrell J. Project Summary/Abstract: Strategies to promote the magnitude and quality of T cell and antibody responses following immunization have broad relevance for the development of new prophylactic and therapeutic vaccines for the treatment of cancer and infectious diseases. Recent s…
David Mitchell Smith · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2020 · $123,468 — Project Summary This application is a proposed renewal of Dr. Davey Smith's K24 grant entitled `Mentoring Translational Research in HIV'. This grant supported the training of over 30 trainees and 80 publications to date. While significant progress in HIV research continues to be made, it is not like…
YOSHIHIRO KAWAOKA · UNIVERSITY OF WISCONSIN-MADISON · 2020 · $206,568 — PROJECT SUMMARY Ebola viruses and other members of the filovirus family cause severe and often lethal infections. While some progress has been made in regards to the development of experimental countermeasures and insights into the highly pathogenic nature of these viruses, there are still many more…
Raul Andino · ALEPH THERAPEUTICS, INC. · 2020 · $250,215 — SUMMARY In 2014 the United States experienced an outbreak of a previously unknown neurological disease with polio-like symptoms later known as acute flaccid myelitis (AFM). A biennial surge in cases of AFM in 2016 and 2018 has alarmed public health officials. Since then, rapidly accumulating clinic…
Antonella Casola · UNIVERSITY OF TEXAS MED BR GALVESTON · 2020 · $197,500 — PROJECT SUMMARY/ABSTRACT Acute respiratory tract infections are a leading cause of morbidity and mortality in children worldwide. Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections in children, elderly and in immunocompromised patients, as well as of asthma exac…
Morgan Meissner · UNIVERSITY OF MINNESOTA · 2020 · $38,509 — Project Summary/Abstract Human immunodeficiency virus (HIV) infects 37 million people globally and has killed over 39 million since its emergence in the human population. There are two different types of HIV: type 1 (HIV-1) and type 2 (HIV-2), with the latter exhibiting an attenuated disease phenoty…